Abstract
Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab can be associated with the development of severe infusion reactions (IR) during retreatment. We present the case of two rheumatoid arthritis patients with a history of severe acute IR to infliximab who subsequently underwent successful infusion using a prophylactic treatment with a combination of H1 and H2 receptor blockers, hydrocortisone, and diphenhydramine.
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy*
-
Diphenhydramine / therapeutic use*
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Female
-
Histamine H1 Antagonists / therapeutic use*
-
Histamine H2 Antagonists / therapeutic use*
-
Humans
-
Hydrocortisone / therapeutic use*
-
Infliximab
-
Infusions, Intravenous / adverse effects
-
Retreatment / methods
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Histamine H1 Antagonists
-
Histamine H2 Antagonists
-
Diphenhydramine
-
Infliximab
-
Hydrocortisone